GYG1

Across TCGA pan-cancer cohorts, GYG1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GYG1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GYG1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GYG1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, PDAC, and LUAD are the cancer types where GYG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.879	1.000	.018	54	view →
PDAC	DFS	Tertile	II,III,IV	0.530	0.286	.001	40	view →
LUAD	OS	Median	III,IV	0.747	1.000	.002	18	view →
HNSC	DFS	Quartile	All	0.899	1.000	.009	3	view →
LSCC	OS	Quartile	All	0.635	0.909	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GYG1–COAD (DFS)

Open the COAD breakdown →